|Mr. William M. Greenman||Pres, CEO & Director||1.06M||753.2k||1967|
|Dr. Laurence M. Corash||Co-Founder & Chief Scientific Officer||616.27k||122.5k||1944|
|Mr. Kevin D. Green||VP of Fin. & CFO||598.28k||681.85k||1972|
|Dr. Richard J. Benjamin||Chief Medical Officer||589.22k||243.98k||1960|
|Mr. Vivek K. Jayaraman||Chief Commercial Officer||669.87k||N/A||1975|
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Cerus Corporation’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 7; Compensation: 4.